TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34561265

Group type: EXPERIMENTAL
Intervention: Exercise intervention (three supervised, high-intensity interval training sessions per week for 12 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 66
Study: 36261342

Group type: EXPERIMENTAL
Intervention: Bar attachment retention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Solitary attachment retention
Number of subjects: 50
Study: 33858985

Group type: EXPERIMENTAL
Intervention: Knowledge translation intervention (telephone surveys, 1-year audit with feedback, guidelines package, academic detailing visit)
Number of subjects: 3424

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 3424

Group type: EXPERIMENTAL
Intervention: Knowledge translation intervention
Number of subjects: 3424

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3424
Study: 34362359

Group type: EXPERIMENTAL
Intervention: Physician
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Physician using AI
Number of subjects: 452

Group type: COMPARATOR
Intervention: Automated AI
Number of subjects: 452

Group type: COMPARATOR
Intervention: Physician (vs. automated AI)
Number of subjects: 452

Group type: COMPARATOR
Intervention: AI (vs. physician only)
Number of subjects: 452
Study: 32682996

Group type: EXPERIMENTAL
Intervention: Diabetes Education + text-message-based Positive Affect intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diabetes Education control condition
Number of subjects: 0
Study: 35987819

Group type: EXPERIMENTAL
Intervention: Oral enteric coating lactoferrin (700 mg/day for at least 28 consecutive days)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Improved microbiota after lactoferrin supplementation
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (non-RIF)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (RIF)
Number of subjects: 117
Study: 33949022

Group type: EXPERIMENTAL
Intervention: Surgery Start Time (SST) - Afternoon implant placement
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Pre-placement ridge augmentation
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Intra-operative complications
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Simultaneous soft tissue grafting
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Simultaneous bone grafting
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Placement with sedation
Number of subjects: 201
Study: 32268191

Group type: EXPERIMENTAL
Intervention: Fast disintegrating and dissolving Aspirin® tablet (FDDT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular Aspirin® tablet (RT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FDDT with food
Number of subjects: 30

Group type: COMPARATOR
Intervention: RT under fed conditions
Number of subjects: 30
Study: 35718771

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (SBP 110–120 mmHg) in SPRINT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (SBP 120–130 mmHg) in SPRINT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (SBP 110–120 mmHg) in ACCORD-BP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (SBP 120–130 mmHg) in ACCORD-BP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Achieved very low BP levels
Number of subjects: 0
Study: 32252803

Group type: EXPERIMENTAL
Intervention: Physical exercise augmented cognitive behaviour therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33577989

Group type: EXPERIMENTAL
Intervention: Email
Number of subjects: 57

Group type: COMPARATOR
Intervention: Attachment
Number of subjects: 57
Study: 32047155

Group type: EXPERIMENTAL
Intervention: Robot-assisted supermicrosurgical lymphatico-venous anastomosis (LVA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual supermicrosurgical lymphatico-venous anastomosis (LVA)
Number of subjects: 0
Study: 36229115

Group type: EXPERIMENTAL
Intervention: Group Triple P‐Positive Parenting Program plus Building Coparenting Alliance
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 100
Study: 33666594

Group type: COMPARATOR
Intervention: Iron Path app (IP)
Number of subjects: 27
Study: 33273714

Group type: EXPERIMENTAL
Intervention: Rapid lateral flow immunoassay for fluorescence detection of SARS-CoV-2 RNA
Number of subjects: 670

Group type: COMPARATOR
Intervention: Quantitative PCR with reverse transcription (ground truth)
Number of subjects: 670
Study: 36175613

Group type: EXPERIMENTAL
Intervention: MUA plus exercise (EX)
Number of subjects: 134

Group type: COMPARATOR
Intervention: CLX plus exercise (EX)
Number of subjects: 134
Study: 34702760

Group type: EXPERIMENTAL
Intervention: Th2 cytokines added to an in vitro three-dimensional human skin model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal human skin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro three-dimensional skin model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 33561587

Group type: EXPERIMENTAL
Intervention: LET monitoring (LET[+])
Number of subjects: 86

Group type: COMPARATOR
Intervention: No LET monitoring (LET[−])
Number of subjects: 86
Study: 33170262

Group type: EXPERIMENTAL
Intervention: Novel cancer therapies
Number of subjects: 191
Study: 33098442

Group type: EXPERIMENTAL
Intervention: Endoscopic aqueductoplasty (EA)
Number of subjects: 20
Study: 32309918

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training for four weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive exercise for eight months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive exercise for eight months (previously published data)
Number of subjects: 0
Study: 33434615

Group type: EXPERIMENTAL
Intervention: Medications for Alcohol Use Disorder (AUD)
Number of subjects: 0
Study: 32591820

Group type: EXPERIMENTAL
Intervention: (lipo)glycopeptides (LGP/GPs) alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: (lipo)glycopeptides (LGP/GPs) in combination with β-lactams
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LGPs (dalbavancin, oritavancin, telavancin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: combinations of LGP/GPs and β-lactams
Number of subjects: 20
Study: 36382660

Group type: EXPERIMENTAL
Intervention: Written counseling
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Oral counseling
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Written + photograph counseling
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Oral + photograph counseling
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Educational intervention overall
Number of subjects: 145
Study: 34715821

Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine for 12 months
Number of subjects: 600

Group type: COMPARATOR
Intervention: Identical placebo for 12 months
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine
Number of subjects: 600

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 600
Study: 33256382

Group type: EXPERIMENTAL
Intervention: Hyperimmune plasma (250-300 ml units with neutralizing antibodies titer ≥1:160)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Hyperimmune plasma
Number of subjects: 46
Study: 35196863

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 24893

Group type: COMPARATOR
Intervention: Clopidogrel (placebo)
Number of subjects: 24893
Study: 34371000

Group type: EXPERIMENTAL
Intervention: Underwater endoscopic mucosal resection (UEMR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional endoscopic mucosal resection (CEMR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both UEMR and CEMR
Number of subjects: 0
Study: 34951060

Group type: EXPERIMENTAL
Intervention: App use group
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Non-app use group
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 34959789

Group type: EXPERIMENTAL
Intervention: 2.5 g/day of Neptune krill oilTM (550 mg EPA/DHA and 150 mg choline)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 35
Study: 34091453

Group type: EXPERIMENTAL
Intervention: Chlormethine gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlormethine ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contact dermatitis
Number of subjects: 0
Study: 36055074

Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 43

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fusion surgery in Supine position
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fusion surgery in Lateral position
Number of subjects: 43
Study: 32872310

Group type: EXPERIMENTAL
Intervention: In-ear SpO2 measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Right index finger measurement (control)
Number of subjects: 0
Study: 35467935

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 4744

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study: 34553690

Group type: EXPERIMENTAL
Intervention: Multi-source feedback (MSF)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Multi-source feedback (MSF) after crossover
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional feedback after crossover
Number of subjects: 32
Study: 36166424

Group type: COMPARATOR
Intervention: Non-HD days
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: HD days
Number of subjects: 517
Study: 32351173

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT‐A)
Number of subjects: 40
Study: 35416910

Group type: EXPERIMENTAL
Intervention: Edoxaban (15 mg once daily)
Number of subjects: 984

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study: 34374082

Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 392

Group type: COMPARATOR
Intervention: White patients
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: KRAS mutant status
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Performance status score of 1
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: ≥3 metastatic sites
Number of subjects: 392
Study: 33374368

Group type: EXPERIMENTAL
Intervention: Daytime green walking
Number of subjects: 48

Group type: COMPARATOR
Intervention: Daytime urban walking
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nighttime green walking
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nighttime urban walking
Number of subjects: 48
Study: 36068576

Group type: EXPERIMENTAL
Intervention: Teaching Recovery Techniques (TRT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 34444820

Group type: EXPERIMENTAL
Intervention: NVP‐1704
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 36466482

Group type: EXPERIMENTAL
Intervention: Assessment plus computer-generated individualized feedback letters
Number of subjects: 1646

Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 1646
Study: 33006446

Group type: EXPERIMENTAL
Intervention: Glass fiber posts
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no glass fiber posts)
Number of subjects: 50
Study: 33917587

Group type: EXPERIMENTAL
Intervention: 4-mm short implants
Number of subjects: 12

Group type: COMPARATOR
Intervention: 10-mm standard implants
Number of subjects: 12
Study: 33001139

Group type: EXPERIMENTAL
Intervention: Oral dexmedetomidine (700 mcg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 35899204

Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavioral therapy for insomnia (iCBT-I; i-Sleep)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (sleep diary monitoring)
Number of subjects: 96
Study: 36112820

Group type: EXPERIMENTAL
Intervention: In-person education through DREAMS health seminar series
Number of subjects: 130

Group type: COMPARATOR
Intervention: Remote (independent reading with telephone support)
Number of subjects: 130
Study: 33978924

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 40
Study: 33069109

Group type: EXPERIMENTAL
Intervention: 4-day stimulus–response compatibility (SRC) approach bias modification treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Corresponding SRC pseudomodification training
Number of subjects: 48
Study: 33136517

Group type: EXPERIMENTAL
Intervention: SGLT2 Inhibition in Combination with Loop Diuretics
Number of subjects: 0
Study: 35580546

Group type: EXPERIMENTAL
Intervention: 4F-PCC for factor Xa inhibitors
Number of subjects: 221

Group type: COMPARATOR
Intervention: 4F-PCC for warfarin
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 4F-PCC for both groups
Number of subjects: 221
Study: 33413599

Group type: EXPERIMENTAL
Intervention: Continuous warfarin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin bridge therapy
Number of subjects: 0
Study: 32152915

Group type: EXPERIMENTAL
Intervention: Multi‐compartmental biorelevant dissolution testing model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation of oral absorption using GastroPlus™ and dissolution data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Characterization of precipitates in the intestinal compartment
Number of subjects: 0
Study: 33511988

Group type: EXPERIMENTAL
Intervention: Bright light treatment (10,000 lux for 30 min/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control treatment (inactivated negative ion generator)
Number of subjects: 69
Study: 34319575

Group type: EXPERIMENTAL
Intervention: 96-case Perceptual Learning Module (PLM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no PLM)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups at six months
Number of subjects: 52
Study: 32207040

Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional observational epidemiology
Number of subjects: 0
Study: 36536711

Group type: EXPERIMENTAL
Intervention: Standard high calorie drink with ginger extract addition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard high calorie drink
Number of subjects: 40
Study: 32236950

Group type: EXPERIMENTAL
Intervention: Ofatumumab + chlorambucil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorambucil monotherapy
Number of subjects: 0
Study: 34886571

Group type: EXPERIMENTAL
Intervention: Planning Health in School programme (PHS‐pro)
Number of subjects: 504
Study: 36378675

Group type: EXPERIMENTAL
Intervention: Internet-based intervention program
Number of subjects: 49

Group type: COMPARATOR
Intervention: Face-to-face interventions (control group)
Number of subjects: 49
Study: 35710449

Group type: EXPERIMENTAL
Intervention: eSyM (electronic symptom management program) integrated into the Epic EHR system
Number of subjects: 0
Study: 33757606

Group type: EXPERIMENTAL
Intervention: anodal tDCS over the right IFG at 1.25 mA combined with inhibitory control training
Number of subjects: 100

Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 100
Study: 32069129

Group type: EXPERIMENTAL
Intervention: RadioEar DD65v2 audiometric headphones
Number of subjects: 25
Study: 36441246

Group type: EXPERIMENTAL
Intervention: Ronch®AP palatal device
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 52
Study: 34016112

Group type: EXPERIMENTAL
Intervention: Paliperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34950944

Group type: EXPERIMENTAL
Intervention: Intensive screening for TB and HIV
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Standard of care (SOC; clinic referral letters)
Number of subjects: 1032
Study: 33823062

Group type: EXPERIMENTAL
Intervention: Occupational dusts
Number of subjects: 2514

Group type: EXPERIMENTAL
Intervention: Chemical vapors
Number of subjects: 2514

Group type: EXPERIMENTAL
Intervention: Exhausts/smokes
Number of subjects: 2514

Group type: EXPERIMENTAL
Intervention: Acids/alkalis
Number of subjects: 2514
Study: 32028117

Group type: EXPERIMENTAL
Intervention: GA 40 mg/mL three-times-weekly (TIW)
Number of subjects: 789

Group type: COMPARATOR
Intervention: GA 20 mg/mL once-daily (QD)
Number of subjects: 789
Study: 35365063

Group type: EXPERIMENTAL
Intervention: BTT with LVAD
Number of subjects: 7759
Study: 34526072

Group type: EXPERIMENTAL
Intervention: i-PUSH program implementation
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: LEAP training tool
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: M-TIBA health wallet
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (no i-PUSH implementation)
Number of subjects: 240
Study: 32203978

Group type: EXPERIMENTAL
Intervention: Canakinumab (50, 150, or 300 mg) subcutaneously once every 3 months
Number of subjects: 8683

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 8683

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8683
Study: 35452919

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Number of subjects: 604
Study: 34108261

Group type: EXPERIMENTAL
Intervention: Everolimus + BNC105P
Number of subjects: 82

Group type: COMPARATOR
Intervention: Everolimus alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Everolimus ± BNC105P
Number of subjects: 82

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 82
Study: 35121250

Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cognitive Restructuring (CR)
Number of subjects: 41
Study: 33355633

Group type: EXPERIMENTAL
Intervention: Mind My Mind (MMM)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Management as Usual (MAU)
Number of subjects: 396
Study: 35572837

Group type: EXPERIMENTAL
Intervention: Moxibustion instrument combined with intermediate frequency electrostatic therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Medium-frequency treatment (Control)
Number of subjects: 200
Study: 32638420

Group type: EXPERIMENTAL
Intervention: Price increase framed as a health-related, earmarked tax
Number of subjects: 603

Group type: COMPARATOR
Intervention: Price increase not framed as a tax
Number of subjects: 603
Study: 36324229

Group type: EXPERIMENTAL
Intervention: Interferon β‐1a (7.5‐30 μg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pegylated interferon β‐1a (31.25‐125 μg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 32095954

Group type: EXPERIMENTAL
Intervention: eHealth treatment for urinary incontinence (UI)
Number of subjects: 373
Study: 32475672

Group type: EXPERIMENTAL
Intervention: Sericea lespedeza (SL) diet
Number of subjects: 4

Group type: COMPARATOR
Intervention: Alfalfa (ALF) diet
Number of subjects: 4

Group type: COMPARATOR
Intervention: Birdsfoot trefoil (BFT) diet
Number of subjects: 4

Group type: COMPARATOR
Intervention: Crown vetch (CV) diet
Number of subjects: 4
Study: 35382796

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery (CamAPS FX application, Dana Diabecare RS insulin pump)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Continuous glucose monitoring (CGM) with usual insulin delivery (Dexcom G6)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 124
Study: 34727936

Group type: EXPERIMENTAL
Intervention: Naprapathy
Number of subjects: 78
Study: 33551858

Group type: EXPERIMENTAL
Intervention: Family-based intervention program comprising 6 to 8 semi-structured sessions over a period of about 6 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition: treatment as usual.
Number of subjects: 0
Study: 34669645

Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional fluid strategy
Number of subjects: 40
Study: 33212067

Group type: EXPERIMENTAL
Intervention: Two-dose CYD-TDV regimen (0.5 mL each dose, administered subcutaneously at months 0, 6, and 12)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Three-dose CYD-TDV regimen (0.5 mL each dose, administered subcutaneously at months 0, 6, and 12)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Two-dose placebo (administered at months 0 and 6) and one dose of CYD-TDV (administered at month 12)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Safety assessment for all groups
Number of subjects: 1050
Study: 32792244

Group type: EXPERIMENTAL
Intervention: SSS07, a humanized rabbit anti-human TNF alpha antibody
Number of subjects: 0
Study: 34642104

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham auricular acupuncture (Control)
Number of subjects: 40
Study: 33731058

Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 32227753

Group type: EXPERIMENTAL
Intervention: Invasive treatment strategy
Number of subjects: 4617

Group type: COMPARATOR
Intervention: Conservative treatment strategy
Number of subjects: 4617
Study: 33383371

Group type: EXPERIMENTAL
Intervention: Babao Dan (BBD) plus lactulose
Number of subjects: 62

Group type: COMPARATOR
Intervention: Lactulose alone
Number of subjects: 62
Study: 33066009

Group type: EXPERIMENTAL
Intervention: Whole eggs (3 eggs/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Choline supplement (choline bitartrate, 400 mg choline/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 23
Study: 35169841

Group type: EXPERIMENTAL
Intervention: Variant of uncertain significance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic diagnosis affecting neurodevelopment but not acute survival
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic etiology of disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pending genetic testing result
Number of subjects: 0
Study: 33631714

Group type: EXPERIMENTAL
Intervention: Nonleisure-time physical activity guidance (NLTPAG)
Number of subjects: 33
Study: 32941098

Group type: EXPERIMENTAL
Intervention: Novel interventions for severe asthma; specific interventions not detailed; crossover design with each participant receiving up to five interventions and at least one placebo.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo; at least one placebo administered to participants.
Number of subjects: 0